M Hebbar

Summary

Affiliation: CHRU de Lille
Country: France

Publications

  1. ncbi Prognostic value of tumoral sialyltransferase expression and circulating E-selectin concentrations in node-negative breast cancer patients
    M Hebbar
    Laboratoire d Oncologie Moléculaire Humaine, Centre Oscar Lambret, Lille, France
    Int J Biol Markers 18:116-22. 2003
  2. pmc Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren's syndrome and systemic sclerosis
    M Hebbar
    Service de Medecine Interne, Hopital Claude Huriez, Lille, France
    Clin Exp Immunol 136:388-92. 2004
  3. ncbi Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study)
    Mohamed Hebbar
    Unité d Oncologie Médicale, Hôpital Huriez CHRU, Lille, France
    Cancer Invest 24:154-9. 2006
  4. ncbi Significance of soluble endothelial molecule E-selectin in patients with breast cancer
    M Hebbar
    Laboratory of Human Molecular Oncology, Centre Oscar Lambret, Lille, France
    Int J Biol Markers 15:15-21. 2000
  5. ncbi Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma
    Mohamed Hebbar
    Unité d Oncologie Médicale, Centre Hospitalo Universitaire, Lille, France
    Oncology 70:154-8. 2006
  6. ncbi Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer
    Mohamed Hebbar
    Department of Medical Oncology, Universitary Hospital, Lille, France
    Anticancer Drugs 17:855-7. 2006
  7. doi Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer
    Mohamed Hebbar
    Medical Oncology Unit, University Hospital, Lille, France
    Oncology 73:185-91. 2007
  8. doi Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer
    Mohamed Hebbar
    Unité d Oncologie Médicale, Centre Hospitalo Universitaire, 1 rue Michel Polonovski, Lille 59037, France
    J Cancer Res Clin Oncol 135:749-52. 2009
  9. doi E-selectin gene S128R polymorphism is associated with poor prognosis in patients with stage II or III colorectal cancer
    Mohamed Hebbar
    Department of Medical Oncology, University Hospital, Lille, France
    Eur J Cancer 45:1871-6. 2009
  10. doi KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?
    M Hebbar
    Department of Medical Oncology, University Hospital, Lille, France
    Eur J Cancer Care (Engl) 19:167-71. 2010

Detail Information

Publications30

  1. ncbi Prognostic value of tumoral sialyltransferase expression and circulating E-selectin concentrations in node-negative breast cancer patients
    M Hebbar
    Laboratoire d Oncologie Moléculaire Humaine, Centre Oscar Lambret, Lille, France
    Int J Biol Markers 18:116-22. 2003
    ..The aim of this study was to assess the prognostic value of tumoral sialyltransferase expression and of circulating soluble E-selectin (sE-selectin) in node-negative breast cancer patients...
  2. pmc Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren's syndrome and systemic sclerosis
    M Hebbar
    Service de Medecine Interne, Hopital Claude Huriez, Lille, France
    Clin Exp Immunol 136:388-92. 2004
    ..These results suggest that soluble CD28 could play an important role in the regulation of autoimmune diseases...
  3. ncbi Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study)
    Mohamed Hebbar
    Unité d Oncologie Médicale, Hôpital Huriez CHRU, Lille, France
    Cancer Invest 24:154-9. 2006
    ..1 percent). Median progression-free and overall survivals were 8.8 and 18.7 months, respectively. Only 2 patients (5.1 percent) had Grade 3 oxaliplatin-related sensory-neuropathy. This schedule had so promising efficacy and safety...
  4. ncbi Significance of soluble endothelial molecule E-selectin in patients with breast cancer
    M Hebbar
    Laboratory of Human Molecular Oncology, Centre Oscar Lambret, Lille, France
    Int J Biol Markers 15:15-21. 2000
    ..5 years), multivariate analyses demonstrated a prognostic value of sE-selectin and tumor size. This study suggests that endothelial activation might play a role in the development of BC. This role seems not to be related to angiogenesis...
  5. ncbi Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma
    Mohamed Hebbar
    Unité d Oncologie Médicale, Centre Hospitalo Universitaire, Lille, France
    Oncology 70:154-8. 2006
    ..We assessed the safety and efficacy of docetaxel, a microtubule inhibitor, in patients with advanced hepatocellular carcinoma (HCC)...
  6. ncbi Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer
    Mohamed Hebbar
    Department of Medical Oncology, Universitary Hospital, Lille, France
    Anticancer Drugs 17:855-7. 2006
    ..These results provide further evidence for the lack of usefulness of epidermal growth factor receptor detection by immunohistochemistry for cetuximab therapy in patients with metastatic colorectal cancer...
  7. doi Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer
    Mohamed Hebbar
    Medical Oncology Unit, University Hospital, Lille, France
    Oncology 73:185-91. 2007
    ..To identify easily available predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer...
  8. doi Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer
    Mohamed Hebbar
    Unité d Oncologie Médicale, Centre Hospitalo Universitaire, 1 rue Michel Polonovski, Lille 59037, France
    J Cancer Res Clin Oncol 135:749-52. 2009
    ..It was initially administered as monotherapy, but is now generally used in combination with 5-fluorouracil or targeted therapies (cetuximab or bevacizumab), with various doses...
  9. doi E-selectin gene S128R polymorphism is associated with poor prognosis in patients with stage II or III colorectal cancer
    Mohamed Hebbar
    Department of Medical Oncology, University Hospital, Lille, France
    Eur J Cancer 45:1871-6. 2009
    ..This polymorphism detection may permit better selection of patients suitable for adjuvant therapy, especially among those with stage II disease...
  10. doi KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?
    M Hebbar
    Department of Medical Oncology, University Hospital, Lille, France
    Eur J Cancer Care (Engl) 19:167-71. 2010
    ..of objective response constantly observed in retrospective analyses in patients with a tumour presenting a KRAS mutation definitively exclude these patients while stable disease (and potentially a slight gain in survival) may be obtained?..
  11. doi Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer
    Mohamed Hebbar
    Department of Medical Oncology, University Hospital, Lille, France
    Cancer Treat Rev 35:668-75. 2009
    ..Ongoing and planned trials will assess the addition of anti-angiogenic and anti-epidermal growth factor receptor agents to chemotherapy regimens...
  12. ncbi [Pulmonary hypertension screening in systemic scleroderma: a cohort study of 67 patients]
    D Launay
    Service de Medecine Interne, Hopital Claude Huriez CHRU, 59037 Lille, France
    Rev Med Interne 22:819-29. 2001
    ..A good knowledge of the clinical, biological and functional features of pulmonary hypertension in systemic sclerosis is therefore necessary to suspect and to diagnose pulmonary hypertension as early as possible...
  13. ncbi Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study
    T Andre
    Hopital Tenon, Department of Medical Oncology, Paris, France
    Ann Oncol 18:77-81. 2007
    ..Celecoxib is an anti-cyclooxygenase-2 drug with anti-neoplastic properties. In the present study, celecoxib was evaluated in combination with FOLFOX7 regimen and as a single agent in maintenance therapy...
  14. ncbi Relationship between parity and clinical and biological features in patients with systemic sclerosis
    D Launay
    , H pital Claude Huriez, CHRU, Lille, France
    J Rheumatol 28:509-13. 2001
    ..6 vs 25.4 +/- 13.4 yrs; p < 0.05). CONCLUSION: Pregnancy related microchimerism could be preferentially associated with limited SSc and pulmonary fibrosis. Microchimerism may be facilitated in cases in which the fetus is female...
  15. ncbi Docetaxel therapy for advanced hepatocellular carcinoma developed in healthy liver: report of three cases
    O Romano
    Department of Medical Oncology, University Hospital, Lille, France
    J Chemother 20:518-20. 2008
    ..These results suggest that chemotherapy, and especially docetaxel, could be safe and effective in patients with HCC developed in healthy liver, and should be assessed in specific trials...
  16. ncbi FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study
    C Ferte
    Department of Medical Oncology, University Hospital, Lille, France
    J Chemother 23:358-61. 2011
    ..To conclude, FOLFIRI regimen appears quite active, with an acceptable safety profile in patients with advanced esophageal or junctional adenocarcinoma...
  17. ncbi Aerosolized iloprost in CREST syndrome related pulmonary hypertension
    D Launay
    Department of Internal Medicine, Functional Cardiac Exploration, Regional University Hospital, Lille, France
    J Rheumatol 28:2252-6. 2001
    ..However, patients who could benefit from this treatment will probably have to undergo careful criteria selection...
  18. ncbi [Wegener's granulomatosis in the elderly patient]
    A L Fauchais
    Service de Medecine Interne, Hopital Claude Huriez, CHRU, Place de Verdun, 59037 Lille, France
    Rev Med Interne 22:127-31. 2001
    ..To determine aged-related variations in clinical and biological presentation and outcome in Wegener's granulomatosis...
  19. doi Inhibition of tissue factor-factor VIIa proteolytic activity blunts hepatic metastasis in colorectal cancer
    Philippe Zerbib
    Inserm ERI 9, Faculté de Médecine Lille, France Université de Lille 2, EA2693, Lille, France
    J Surg Res 153:239-45. 2009
    ..We thus hypothesized that inhibition of the TF pathway by active site-blocked FVIIa (FFR-FVIIa) may prevent the development of hepatic metastasis in CRC...
  20. ncbi [Psychiatric complications of corticoid therapy in the elderly over 65 years of age treated for Horton disease]
    A L Fauchais
    Service de Medecine Interne A, Hopital Claude Huriez, CHRU, 59037 Lille, France
    Rev Med Interne 23:828-33. 2002
    ..To analyse steroid psychiatric related complications in aged (> 65 years old) with temporal arteritis (TA)...
  21. ncbi Expression of nerve growth factor receptors and their prognostic value in human breast cancer
    S Descamps
    , Centre Oscar Lambret, 59020 Lille, France
    Cancer Res 61:4337-40. 2001
    ..In Cox multivariate analyses, TrkA was not a prognostic parameter. This study demonstrates the expression of NGFRs in breast cancer and points out that patients with high levels of TrkA have a more favorable overall survival prognosis...
  22. ncbi [Systemic sclerosis and pregnancy]
    D Launay
    Service de Medecine Interne, Hopital Claude Huriez, CHRU Lille, Rue Michel Polonovski, 59037 Lille, France
    Rev Med Interne 23:607-21. 2002
    ..Pregnancy in a patient with systemic sclerosis (SSc) may pose a double problem to the medical team: influence of SSc on pregnancy and consequences of pregnancy to SSc manifestations...
  23. ncbi Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases
    S Truant
    Department of Digestive and Transplantation Surgery, University Hospital, Hospital Huriez, 59037 Lille Cedex, France
    Br J Surg 92:362-9. 2005
    ....
  24. doi O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 59020, Lille, France
    Invest New Drugs 26:561-5. 2008
    ..Nowadays, there is no consensual and effective treatment in metastatic uveal melanoma (MUM). Numerous preclinical data (for example, 75% of MUM express c-kit) suggest that imatinib mesylate (IM) may be a potential treatment of UMM...
  25. ncbi Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in peripheral blood mononuclear cells in systemic sclerosis
    David Launay
    Department of Internal Medicine, Regional University Hospital Claude Huriez, Lille, France
    J Rheumatol 31:88-95. 2004
    ..To assess sialyltransferase expression in peripheral blood mononuclear cells (PBMC) of patients with systemic sclerosis (SSc) and to correlate this expression with the clinical features of the disease...
  26. ncbi [Targeting the epidermal growth factor receptor in colorectal cancer: clinical results]
    Antoine Adenis
    Département de Cancérologie Digestive et Urologique, Centre Oscar Lambret, BP 307, 59020 Lille Cedex
    Bull Cancer 92:S21-8. 2005
    ..At this point of the clinical development of these all EGFR inhibitors (monoclonal antibodies or tyrosine kinase inhibitors) in MCRC, informative data from randomized studies are urgently needed...
  27. doi Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study
    Amani Asnacios
    Department of Hepato gastro enterology, Pitie Salpetriere Hospital, Paris, France
    Cancer 112:2733-9. 2008
    ....
  28. ncbi Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study
    Julien Taieb
    Service d Hepatogastroenterologie, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75013 Paris, France
    J Clin Oncol 23:502-9. 2005
    ..To evaluate the efficacy and tolerability of the metastatic irinotecan plus oxaliplatin (MIROX) strategy (adjuvant FOLFOX-7 followed by FOLFIRI), in patients with resectable metastatic colorectal cancer...
  29. ncbi Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level
    Valerie Boige
    Gastrointestinal Oncology Unit, Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Eur J Cancer 42:456-9. 2006
    ..51 and 3 ULN. However, the antitumour activity of single agent CPT-11 was not significant in advanced HCC...
  30. ncbi Association between systemic sclerosis and breast cancer: eight new cases and review of the literature
    David Launay
    Service de Medecine Interne, CHRU, Hopital Claude Huriez, 1 Place Verdun, 59037 Lille, France
    Clin Rheumatol 23:516-22. 2004
    ..SSc is probably not a paraneoplastic disease since the anticancer treatment has no influence on the evolution of SSc. However, it can be suggested that SSc could be a disease facilitating breast cancer and/or metastases development...